Key Facts

Clinical trials and epidemiological studies presented at international medical forums demonstrated that Glucagon-Like Peptide-1 (GLP-1) receptor agonists (such as semaglutide and liraglutide) offer therapeutic benefits extending well beyond weight management and glycemic control. Large multi-centre cardiovascular outcome trials (CVOTs) established that GLP-1 drugs produce significant risk reductions in major adverse cardiovascular events (MACE), including myocardial infarction, stroke, heart failure hospitalisation, and the progression of chronic kidney disease (CKD) in diabetic and high-risk non-diabetic patients. Endocrinologists emphasized that these pharmacotherapies are shifting treatment paradigms from symptomatic management towards holistic multi-organ cardiometabolic protection.

GK Context

GLP-1 is a natural incretin hormone secreted by the L-cells of the small intestine in response to nutrient intake, which enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon release, delays gastric emptying, and centrally promotes satiety in the brain's hypothalamus. While initial formulations were developed strictly for Type-2 Diabetes Mellitus, second-generation synthetic analogues have received global regulatory clearances for chronic obesity and cardiovascular risk mitigation. In India, public health experts note that patent expirations over the coming years could spur domestic generic manufacturing, dramatically lowering costs for non-communicable disease (NCD) care.